The DOI matches its Crossref record; 379 of the 385 references it cites were found in a registry or an index; 10 of the 34 sources its claims cite were checked for support.
Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis
Open accessAbstract
The epidemiology of bacterial meningitis has changed as a result of the widespread use of conjugate vaccines and preventive antimicrobial treatment of pregnant women. Given the significant morbidity and mortality associated with bacterial meningitis, accurate information is necessary regarding the important etiological agents and populations at risk to ascertain public health measures and ensure appropriate management. In this review, we describe the changing epidemiology of bacterial meningitis in the United States and throughout the world by reviewing the global changes in etiological agents followed by specific microorganism data on the impact of the development and widespread use of conjugate vaccines. We provide recommendations for empirical antimicrobial and adjunctive treatments for clinical subgroups and review available laboratory methods in making the etiological diagnosis of bacterial meningitis. Finally, we summarize risk factors, clinical features, and microbiological diagnostics for the specific bacteria causing this disease.
Overview
CoChat Summary
TL;DR
This narrative review describes the changing global epidemiology of acute bacterial meningitis, emphasizing the impact of conjugate vaccines, and summarizes laboratory diagnosis and antimicrobial treatment by clinical subgroup and pathogen. It reports major declines in Hib and pneumococcal meningitis after vaccination, while noting serotype replacement and a persistent high burden in developing countries.
Key findings
- Before Hib conjugate vaccine, *H. influenzae* caused 45–48% of US bacterial meningitis cases; afterward it accounted for 7%. Industrialized nations saw >90% decreases (some >95%), developing-country vaccine efficacy was 88–94%, and the mean age of US cases rose from 15 months in 1986 to 25 years in 1995.
- *S. pneumoniae* became the most common agent in the US and Europe, accounting for 61% of US cases. Heptavalent pneumococcal conjugate vaccine efficacy was 97.4% against vaccine serotypes; pneumococcal meningitis declined 59% in children <2 years, and incidence fell from 0.8 to 0.55 per 100,000 (33% decline), though serotypes 19A, 22F, and 35B emerged.
- In 2008 US meningococcal disease, serogroups B (32%), C (32%), and Y (24%) predominated, causing meningitis in 53% of cases. The UK serogroup C conjugate vaccine program reduced serogroup C invasive disease by 81% overall, with short-term effectiveness of 92% in toddlers and 97% in adolescents and a 66% reduction in carriage among students aged 15–17.
- Historical CDC 1978–1981 data included 13,974 cases, with an overall attack rate of 3.0 per 100,000; children <1 year had 76.7 per 100,000, and *H. influenzae*, *N. meningitidis*, and *S. pneumoniae* caused >80% of cases.
Methods
- Narrative review of global epidemiology, conjugate vaccine impact, laboratory diagnosis, and antimicrobial/adjunctive therapy by clinical subgroup and specific pathogen.
- Synthesizes data from CDC and other surveillance systems, vaccine trials, and published studies; no systematic search, inclusion criteria, or meta-analysis is described.
- Main analysis is qualitative synthesis and expert recommendations, not primary data collection.
Limitations
- The paper states that historical incidence studies were retrospective, used small populations, and had significant underreporting; the 1978–1981 CDC study lacked active case detection.
- The paper notes no US epidemiological data on the tetravalent meningococcal conjugate vaccine’s impact and that 23-valent pneumococcal polysaccharide vaccine efficacy against meningitis has never been proven, with wide confidence intervals.
- Evident from the text: as a narrative review, it lacks systematic search and quality appraisal and relies on heterogeneous surveillance and vaccine studies.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 2 Not valid · 13 Not checked · 3 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In other developing countries, the overall vaccine efficacy rate has ranged from 88 to 94% (Table 1) (3, 78, 83, 122).”
What the sources say
- Not checked — no full text of the sourcecites [3] source
- Partly supportedcites [78] sourceExperimental — accuracy not yet measured
The Results report 88% Hib vaccine effectiveness among children under 5 in Kenya, supporting the lower end of the claimed range. The Introduction reports 95% efficacy in The Gambia, not 94%, and the paper does not establish an overall 88–94% range across developing countries. The Kenyan estimate is program effectiveness, rather than vaccine efficacy measured in a trial. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [83] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Strong evidence of herd immunity was observed when H. influenzae type b disease decreased in U.S. children less than 1 year of age before the vaccine was licensed for use in this age group (2).”
What the sources say
- Not checked — no full text of the sourcecites [2] source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Carriage of serogroup C among students aged 15 to 17 years was also reduced by 66% (200).”
What the sources say
- Not checked — no full text of the sourcecites [200] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Declines in the incidence of pneumococcal meningitis have been observed by other studies that did not show evidence of an emergence of disease caused by serotype replacement (59).”
What the sources say
- Not checked — no full text of the sourcecites [59] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The benefit of H. influenzae type b conjugate vaccine, however, may open up opportunities for non-type-b strains to cause invasive disease.”
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, appropriate aetiological diagnoses of meningitis and encephalitis with traditional microbiological methods, i.e., cultures, is challenging due to low diagnostic performance, long time to complete, and the previous use of antibimicrobials.6”
From Biofire FilmArray Meningitis/Encephalitis panel for the aetiological diagnosis of central nervous system infections: A systematic review and diagnostic test accuracy meta-analysis (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The low pre-test probability of CNS infections as a result of a significant decrease in recent years,6,41 explains the low prevalence and a high FP rate.”
From Biofire FilmArray Meningitis/Encephalitis panel for the aetiological diagnosis of central nervous system infections: A systematic review and diagnostic test accuracy meta-analysis (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The morbidity and mortality of these infections can be high, particularly with bacterial meningitis, which can be rapidly life threatening”
From Multicenter Evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for Detection of Bacteria, Viruses, and Yeast in Cerebrospinal Fluid Specimens (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While CSF culture is the gold standard for the diagnosis of bacterial meningitis, its sensitivity varies between 50% and 90%, dependent on bacterium type and bacterial load, and decreases when antibiotic treatment has been started prior to the CSF collection (12–14).”
From Molecular diagnostics in cerebrospinal fluid for the diagnosis of central nervous system infections (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among the reasons for failure of primary culture is antibiotic administration prior to lumbar puncture [39].”
From Implementation of the FilmArray ME panel in laboratory routine using a simple sample selection strategy for diagnosis of meningitis and encephalitis (2020) · cites this paper as [39]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Bernard, G. R., Vincent, J.-L., Laterre, P.-F., LaRosa, S. P., Dhainaut, J.-F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441001 · Cited by 6,132
Mermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.
Schrag, S. D., Gorwitz, R. J., Fultz-Butts, K., & Schuchat, A. (2002) · PubMed · Cited by 3,349
Practice Guidelines for the Management of Bacterial Meningitis
Tunkel, A. R., Hartman, B. J., Kaplan, S. L., Kaufman, B. A., Roos, K. L., Scheld, W. M., & Whitley, R. J. (2004) · Clinical Infectious Diseases · doi:10.1086/425368 · Cited by 2,308
Self-citationEfficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
BLACK, S., SHINEFIELD, H., FIREMAN, B., LEWIS, E., RAY, P., HANSEN, J. R., ELVIN, L., ENSOR, K. M., HACKELL, J., SIBER, G., et al. (2000) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200003000-00003 · Cited by 2,293
Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Lynfield, R., Reingold, A., Cieslak, P. R., Pilishvili, T., Jackson, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022823 · Cited by 2,228
(2013) · Pediatrics · doi:10.1542/peds.2013-2511 · Cited by 1,845
Clinical features and prognostic factors in adults with bacterial meningitis
van de Beek, D., de Gans, J., Spanjaard, L., Weisfelt, M., Reitsma, J. B., & Vermeulen, M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040845 · Cited by 1,639
Peltola, H. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.302-317.2000 · Cited by 1,364
Acute Bacterial Meningitis in Adults -- A Review of 493 Episodes
Durand, M. L., Calderwood, S. B., Weber, D. J., Miller, S. I., Southwick, F. S., Caviness, V. S., & Swartz, M. N. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301073280104 · Cited by 1,344
Research works printed but not linked: 2
- Centers for Disease Control and Prevention. 2008. Progress in introduction of pneumococcal conjugate vaccine—worldwide, 2000-2008. MMWR Morb. Mortal. Wkly. Rep.57:1148-1151.
- Greenwood, B. M. 1987. The epidemiology of acute bacterial meningitis in tropical Africa, p. 93-113. In J. D. Williams and J. Burnie (ed.), Bacterial meningitis. Academic Press, London, United Kingdom.
Cited by
ESCMID guideline: diagnosis and treatment of acute bacterial meningitis
van de Beek, D., Cabellos, C., Dzupova, O., Esposito, S., Klein, M., Kloek, A. T., Leib, S. L., Mourvillier, B., Ostergaard, C., Pagliano, P., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.01.007 · Cited by 919
Self-citationCorticosteroids for acute bacterial meningitis
Brouwer, M. C., McIntyre, P., Prasad, K., & van de Beek, D. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004405.pub5 · Cited by 809
Self-citationLeber, A. L., Everhart, K., Balada-Llasat, J.-M., Cullison, J., Daly, J., Holt, S., Lephart, P., Salimnia, H., Schreckenberger, P. C., DesJarlais, S., et al. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00730-16 · Cited by 609
“Gram stain has been assessed in cases of suspected meningitis and reported to have sensitivity ranging from 10 to 93%, depending on the organism and population being tested (1), and a near 100% specificity (21).”
BackgroundSecondary bacterial infections associated with influenza pandemics
Morris, D. E., Cleary, D. W., & Clarke, S. C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01041 · Cited by 576
“H. influenzae serotype B was a major cause of invasive disease (Wenger, 1998; Murphy, 2003; Chin et al., 2005; Brouwer et al., 2010) although widespread implementation of the Hib vaccine has significantly reduced the burden of disease (Rosenstein and Perkins, 2000).”
BackgroundPathogenesis and Pathophysiology of Pneumococcal Meningitis
Mook-Kanamori, B. B., Geldhoff, M., van der Poll, T., & van de Beek, D. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-11 · Cited by 492
“Invasive pneumococcal disease is seen during the extremes of age (less than 2 or more than 50 years of age); in patients with underlying conditions, such as splenectomy or asplenic states, sickle cell disease, multiple myeloma, hypogammaglobulinemia, alcoholism, chronic liver or kidney disease, malignancy, malnutritio…”
Background
Metadata
- Authors
- Brouwer, M. C., Tunkel, A. R., & van de Beek, D.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Monmouth Medical Center (US)
- Department of Neurology, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2010-07
- Volume
- 23
- Issue
- 3
- Pages
- 467-492
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- PMC
- PMC2901656
- OpenAlex
- W2108054631
- Cited by
- 930
- References
- 385
- Citations by year
- 2026: 55 · 2025: 51 · 2024: 70 · 2023: 57 · 2022: 78 · 2021: 73 · 2020: 68 · 2019: 65 · 2018: 57 · 2017: 77 · 2016: 83 · 2015: 56 · 2014: 40 · 2013: 45 · 2012: 37
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Clinical Microbiology Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (916.76.023)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- acute bacterial meningitis, epidemiology, conjugate vaccines, etiological agents, empirical antimicrobial treatment, adjunctive therapy, laboratory diagnosis, risk factors, clinical features, Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b, Haemophilus influenzae type a, Listeria monocytogenes, Salmonella meningitis, Escherichia coli meningitis, meningococcal serogroups
- MeSH terms
- Anti-Bacterial Agents, Bacteria, Bacterial Vaccines, Bacteriological Techniques, Cross Infection, Humans, Immunocompromised Host, Meningitis, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis. https://app.cochat.ai/papers/10.1128/cmr.00070-09
- The paper
- Brouwer, M. C., Tunkel, A. R., & van de Beek, D. (2010). Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis. Clinical Microbiology Reviews. https://doi.org/10.1128/cmr.00070-09
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.